Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patients-Reference-Cited by-同舟云学术

Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patients

Published:2022-12-02 Issue: Volume: Page:
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Asano Arisa¹,Ri Masaki¹²^ORCID,Masaki Ayako¹³,Maeda Yasuhiro⁴,Tachita Takuto¹⁵^ORCID,Hirade Kentaro¹,Marumo Yoshiaki¹,Nakashima Takahiro¹,Hagiwara Shinya¹,Kinoshita Shiori¹,Suzuki Tomotaka¹,Narita Tomoko¹,Kusumoto Shigeru¹,Komatsu Hirokazu¹,Inagaki Hiroshi³,Iida Shinsuke¹

Affiliation:

1. Department of Hematology and Oncology Nagoya City University Institute of Medical and Pharmaceutical Sciences Nagoya Japan

2. Department of Blood Transfusion and Cell Therapy Nagoya City University Hospital Nagoya Japan

3. Department of Pathology and Molecular Diagnostics Nagoya City University Institute of Medical and Pharmaceutical Sciences Nagoya Japan

4. Open Facility Center Fujita Health University Toyoake Japan

5. Department of Gastroenterology and Hematology Hirosaki University Graduate School of Medicine Hirosaki Japan

Funder

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3108

Reference32 articles.

1. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

2. Cancer immunoediting and immune dysregulation in multiple myeloma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone;Cancer Medicine;2024-07

2. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy;Expert Review of Anticancer Therapy;2023-02-09